Literature DB >> 6741804

Randomized comparison of intravenous versus intracoronary streptokinase for myocardial infarction.

E L Alderman, K R Jutzy, L E Berte, R G Miller, J P Friedman, W P Creger, M Eliastam.   

Abstract

The efficacy of intravenous (i.v.) thrombolytic therapy has not been firmly established in comparison with the intracoronary (i.c.) route of administration. In a randomized trial of 28 patients who underwent angiography before and during i.v. and i.c. administration of streptokinase (STK), recanalization was achieved in 73% of patients who received the drug by the i.c. route, compared with 62% of patients who received the drug by the i.v. route (difference not significant). Reopening took 28 minutes for i.c. STK and 39 minutes for i.v. STK. Patients in whom recanalization was successful using either route of administration had shorter euglobulin lysis times and lower fibrinogen levels than did patients in whom it was not successful (p less than 0.05). Bleeding complications were closely correlated with heparinization after thrombolysis rather than with STK itself. These results in a limited patient series suggest that early administration of i.v. STK in the emergency department may yield recanalization rates similar to those for the i.c. route and may benefit myocardial preservation by restoring flow much earlier.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6741804     DOI: 10.1016/0002-9149(84)90297-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Intravenous fibrinolytic therapy of acute myocardial infarction: new perspectives from plasminogen activators?

Authors:  W Kasper; T Meinertz; H Just
Journal:  Klin Wochenschr       Date:  1986-04-01

4.  What proportion of patients with myocardial infarction are suitable for thrombolysis?

Authors:  N Murray; J Lyons; C Layton; R Balcon
Journal:  Br Heart J       Date:  1987-02

Review 5.  Thrombolytic therapy in acute myocardial infarction. A perspective.

Authors:  S Sherry
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  A D Timmis; B Griffin; J C Crick; J S Flax; E Sowton
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 7.  The History of Primary Angioplasty and Stenting for Acute Myocardial Infarction.

Authors:  Nathaniel R Smilowitz; Frederick Feit
Journal:  Curr Cardiol Rep       Date:  2016-01       Impact factor: 2.931

Review 8.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

Review 9.  Adverse reactions to thrombolytic agents. Implications for coronary reperfusion following myocardial infarction.

Authors:  J Nazari; R Davison; K Kaplan; D Fintel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Jul-Aug

Review 10.  Anisoylated plasminogen streptokinase activator complex (APSAC). A review of its mechanism of action, clinical pharmacology and therapeutic use in acute myocardial infarction.

Authors:  J P Monk; R C Heel
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.